These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35917841)

  • 1. Synergism of interferon-beta with antiviral drugs against SARS-CoV-2 variants.
    Bojkova D; Stack R; Rothenburger T; Kandler JD; Ciesek S; Wass MN; Michaelis M; Cinatl J
    J Infect; 2022 Nov; 85(5):573-607. PubMed ID: 35917841
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice.
    Jeong JH; Chokkakula S; Min SC; Kim BK; Choi WS; Oh S; Yun YS; Kang DH; Lee OJ; Kim EG; Choi JH; Lee JY; Choi YK; Baek YH; Song MS
    Antiviral Res; 2022 Dec; 208():105430. PubMed ID: 36209984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viral target and metabolism-based rationale for combined use of recently authorized small molecule COVID-19 medicines: Molnupiravir, nirmatrelvir, and remdesivir.
    Yan D; Yan B
    Fundam Clin Pharmacol; 2023 Aug; 37(4):726-738. PubMed ID: 36931725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2.
    Wagoner J; Herring S; Hsiang TY; Ianevski A; Biering SB; Xu S; Hoffmann M; Pöhlmann S; Gale M; Aittokallio T; Schiffer JT; White JM; Polyak SJ
    Microbiol Spectr; 2022 Oct; 10(5):e0333122. PubMed ID: 36190406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic Activity of Remdesivir-Nirmatrelvir Combination on a SARS-CoV-2 In Vitro Model and a Case Report.
    Gidari A; Sabbatini S; Schiaroli E; Bastianelli S; Pierucci S; Busti C; Saraca LM; Capogrossi L; Pasticci MB; Francisci D
    Viruses; 2023 Jul; 15(7):. PubMed ID: 37515263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination regimen of nirmatrelvir/ritonavir and molnupiravir for the treatment of persistent SARS-CoV-2 infection: A case report and a scoping review of the literature.
    Marangoni D; Antonello RM; Coppi M; Palazzo M; Nassi L; Streva N; Povolo L; Malentacchi F; Zammarchi L; Rossolini GM; Vannucchi AM; Bartoloni A; Spinicci M
    Int J Infect Dis; 2023 Aug; 133():53-56. PubMed ID: 37150351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Variants of SARS-CoV-2 and Next Generation of COVID-19 Treatments.
    Khiali S; Entezari-Maleki T
    J Clin Pharmacol; 2022 Sep; 62(9):1055-1058. PubMed ID: 35522372
    [No Abstract]   [Full Text] [Related]  

  • 9. Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.
    Schilling WHK; Jittamala P; Watson JA; Boyd S; Luvira V; Siripoon T; Ngamprasertchai T; Batty EM; Cruz C; Callery JJ; Singh S; Saroj M; Kruabkontho V; Ngernseng T; Tanglakmankhong N; Tubprasert J; Abdad MY; Madmanee W; Kouhathong J; Suwannasin K; Pagornrat W; Piaraksa N; Hanboonkunupakarn P; Hanboonkunupakarn B; Poovorawan K; Potaporn M; Srisubat A; Loharjun B; Taylor WRJ; Chotivanich V; Chotivanich K; Imwong M; Pukrittayakamee S; Dondorp AM; Day NPJ; Teixeira MM; Piyaphanee W; Phumratanaprapin W; White NJ;
    Lancet Infect Dis; 2024 Jan; 24(1):36-45. PubMed ID: 37778363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19.
    Sutanto ST; Sinto R; Pasaribu A; Shakinah S
    Acta Med Indones; 2022 Oct; 54(4):638-644. PubMed ID: 36624705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PF-07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: Implications for COVID-19 patients.
    Hau RK; Wright SH; Cherrington NJ
    Clin Transl Sci; 2022 Jul; 15(7):1599-1605. PubMed ID: 35505633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants.
    Cho J; Shin Y; Yang JS; Kim JW; Kim KC; Lee JY
    Antiviral Res; 2023 Jun; 214():105609. PubMed ID: 37086978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molnupiravir and Its Antiviral Activity Against COVID-19.
    Tian L; Pang Z; Li M; Lou F; An X; Zhu S; Song L; Tong Y; Fan H; Fan J
    Front Immunol; 2022; 13():855496. PubMed ID: 35444647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Drug Development and Medicinal Chemistry Approaches for the Treatment of SARS-CoV-2 Infection and COVID-19.
    Ghosh AK; Mishevich JL; Mesecar A; Mitsuya H
    ChemMedChem; 2022 Nov; 17(22):e202200440. PubMed ID: 36165855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2.
    Fiaschi L; Dragoni F; Schiaroli E; Bergna A; Rossetti B; Giammarino F; Biba C; Gidari A; Lai A; Nencioni C; Francisci D; Zazzi M; Vicenti I
    Viruses; 2022 Jun; 14(7):. PubMed ID: 35891355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral drugs against SARS-CoV-2.
    Aiello TF; García-Vidal C; Soriano A
    Rev Esp Quimioter; 2022 Oct; 35 Suppl 3(Suppl 3):10-15. PubMed ID: 36285850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral Efficacy of Molnupiravir for COVID-19 Treatment.
    Bai Y; Shen M; Zhang L
    Viruses; 2022 Apr; 14(4):. PubMed ID: 35458493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy.
    Ciccimarra F; Luxi N; Bellitto C; L' Abbate L; De Nardo P; Savoldi A; Yeomans A; Molokhia M; Tacconelli E; Trifirò G
    BioDrugs; 2023 Sep; 37(5):675-684. PubMed ID: 37148526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of molnupiravir and interferon for the treatment of SARS-CoV-2 in golden Syrian hamster.
    Liu D; Leung KY; Zhang R; Lam HY; Fan Y; Xie X; Chan KH; Hung IF
    J Med Virol; 2024 Sep; 96(9):e29901. PubMed ID: 39210614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.